Efficacy of cisplatin and cyclophosphamide combination for recurrent and metastatic carcinoma of the uterine cervix

The efficacy of a combination of cyclophosphamide and cisplatin in patients with metastatic and recurrent carcinoma of the cervix, was tested. Thirty patients were included in the study. Initially, 27 patients (90%) had received pelvic radiation and intracavitary boost and one patient was additionally given paraaortic radiation. Cisplatin was given at 75 mg/m2 followed by cyclophosphamide at 750 mg/m2 on day 1 with three weekly intervals for a maximum of six cycles. All patients received a median of four cycles of chemotherapy. The overall response rate for all eligible patients was 20% (continuous CR: 1, CR: 1, PR: 4 patients). Overall response rate and progressive response in patients with relapse within the previous radiation field were 9.5% and 66.7%, respectively; while for patients who had recurrent disease outside any irradiated area both were 44.4%. Eighteen patients (60%) had early withdrawal from the planned schedule, which was due to patient incompliance in seven patients (23.3%), disease progression in ten (33.3%) and early death after the first cycle in one patient (3.3%). Anemia was the most frequent toxicity, necessiating 24 transfusions in nine patients (30%). WHO grade 3 and 4 toxicity were anemia: 13 (43.3%), leucopenia: one (3.3%), thrombocytopenia: two (6.6%), renal: one, emesis: nine (30.0%) patients. The median survival duration for all eligible patients was 11 months. Univariate analysis revealed that progressive response to chemotherapy was the only prognostic factor for survival (7.1 vs 16.8 months, p = 0.003). The combination of cisplatin and cyclophosphamide did not appear to be more active than single agent cisplatin in this patient group with a relatively poor prognosis. Further studies are required to determine a better therapeutic approach for patients with relapsed carcinoma of the cervix.

Recurrent carcinoma of the uterine cervix; Chemotherapy; Cisplatin; Cyclophosphamide

[1] Thigpen T., Vance R.B., Khansur T.:''The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix". Semin. Oneal., 1995, 22 (suppl. 5), 67.

[2] Cannistra S.A., Niloff J.M.: "Cancer of the uterine cervix". N. Engl. J. Med., I 996, 334, 1030.

[3] Alberts D.S., Kronmal R., Baker L.H., Stock-Novack D.L., Surwit E.A., Boutselis J.G., Hannigan E.V.: "Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: A Southwest Oncology Group Study". J. Clin. Oneal., 1987, 5 (11), 1791.

[4] Omura G.A., Blessing J.A., Vaccarello L., Berman M.L., ClarkePearson D.L., Mutch D.G., Anderson B.: "Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study". J. Clin. Oneal., 1997, 15 (1), 165.

[5] Vermorken J.B., Zanetta G., De Oliveira C.F., van der Burg M.E., Lacave A.J., Teodorovic I. et al.: "Randomized phase III trial of bleomycin, vindesine, mitomycin-C and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma of the uterine cervix: An EORTC Gynecological Cancer Cooperative Group Study". Ann. Oneal., 2001, 12, 967.

[6] Lele S.B., Piver M.S., Barlow J.J.: "Cyclophosphamide, Adriamycin, and platinum chemotherapy in treatment of advanced and recurrent cervical carcinoma". Gynecol. Oneal., 1983, 16 (1), 15.

[7] Hoffman M.S., Roberts W.S., Bryson S.C., Kavanagh J.J. Jr., Cavanagh D., Lyman G.H.: "Treatment of recurrent and metastatic cervical cancer with cis-platin, doxorubicin, and cyclophosphamide". Gynecol. Oneal., 1988, 29 (1), 32.

[8] Cervellino J.C., Araujo C.E., Pirisi C., Sanchez 0., Brosto M., Rossi R.: "Ifosfamide and mesna at high doses for the treatment of cancer of the cervix: a GETLAC study". Cancer Chemother. Pharmacol., 1990; 26 (suppl.), S1.

[9] Hannigan E.V., Dinh T.V., Doherty M.G.: "Ifosfamide with mesna in squamous carcinoma of the cervix: phase II results in patients with advanced or recurrent disease". Gynecol. Oneal., 1991, 43(2), 123.

[10] Jobson V.W., Muss H.B., Thigpen J.T., Homesley H.D., Bundy B.: "Chemotherapy of advanced squamous carcinoma of the cervix: a phase 1-11 study of high-dose cisplatin and cyclophosphamide. A pilot study of the Gynecologic Oncology Group". Am. J. Clin. Oneal., 1984, 7 (4), 341.

[11] De Murua E.0., George M., Pejovic M.H., Dewailly J., Wolff J.P.: "Combination cyclophosphamide, adriamycin, and cis-platinum in recurrent and metastatic cervical carcinoma". Gynecol. Oneal., 1987, 26 (2), 225.

[12] Murad A.M., Triginelli S.A., Ribalta J.C.: "Phase II trial of bleomycin, ifosfamide, and carboplatin in metastatic cervical cancer". J. Clin. Oneal., 1994, 12 (I), 55.

[13] Pignata S., De Vivo R., Ricchi P., Perrone F., Botti G., Monfardini S.: "Chemotherapy in squamous cell carcinoma of the cervix uteri: present role and perspectives". Cancer Treat. Rev., 1998, 24 (1), 27.

[14] Bonomi P., Blessing J.A., Stehman F.B., DiSaia P.J., Walton L., Major F.J.: "Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study". J. Clin. Oneal., 1985, 3 (8), 1079.

[15] Thigpen T., Shingleton H., Homesley H., Lagasse L., Blessing J.: "Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group". Cancer, 1981, 48 (4), 899.

[16] Zanetta G., Torri W., Bocciolone L., Lucchini V., Mangioni C.: "Factors predicting response to chemotherapy and survival in patients with metastatic or recurrent squamous cell cervical carcinoma: a multivariate analysis". Gynecol. Oneal., 1995, 58 (1), 58.

[17] Brader K.R., Morris M., Levenback C., Levy L., Lucas K.R., Gershenson D.M.: "Chemotherapy for cervical carcinoma: factors determining response and implications for clinical trial design". J. Clin. Oneal., 1998, 16 (5), 1879.

[18] Papadimitriou C.A., Sarris K., Moulopoulos L.A., Fountzilas G., Anagnostopoulos A., Voulgaris Z. et al.: "Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix". J. Clin. Oneal., 1999, 17 (3), 761.

[19] Lhomme C., Vermorken J.B., Mickiewicz E., Chevalier B., Alvarez A., Mendiola C. et al.: "Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: an EORTC Gynaecological Cancer Cooperative Group Study". Eur. J. Cancer, 2000, 36 (2), 194.

[20] Rose P.G., Blessing J.A., Gershenson D.M., McGehee R.: "Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study". J. Clin. Oneal., 1999, 17 (9), 2676.

[21] Zanetta G., Fei F., Parma G., Balestrino M., Lissoni A., Gabriele A., Mangioni C.: "Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer". Ann. Oneal., 1999, 10 (10), 1171.

[22] Burnett A.F., Roman L.D., Garcia A.A., Muderspach L.I., Brader K.R., Morrow C.P.: "A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix". Gynecol. Oneal., 2000, 76 (1), 63.